Shattuck Labs

Shattuck Labs is a biopharmaceutical company based in the United States that specializes in developing novel protein engineering approaches to create transformational medicines, particularly focusing on tumor necrosis factor (TNF) receptor modulators for the treatment of inflammatory and autoimmune diseases. The company's lead program, SL-325, is a potential first-in-class monoclonal antibody antagonist of death receptor 3 (DR3) designed to address significant unmet medical needs.